Protagonist Therapeutics Inc
Research Protagonist Therapeutics Inc (PTGX) on Bullrun: market cap USD 9.74B, P/E 145.2. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPTGX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 9.74B
- P/E145.2
- Financial periodQ2 2026
- RevenueUSD 213.48M
- Net incomeUSD 162.85M
- Free cash flowUSD 218.88M
Valuation Snapshot
latest market cap is USD 9.74B; P/E is 145.2.
Peer valuation comparison
Latest P/E is 145.22x versus a Healthcare sector median of 24.46x (493.7% above).
Latest P/E is 145.22x versus a United States median of 24.87x (484.0% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 46.02M | -USD 130.15M | USD 56.08M | n/a | -2.05 | USD 128.39M | USD 10.32M | USD 614.71M |
| FY2024 | USD 434.43M | USD 275.19M | USD 182.80M | n/a | 4.23 | USD 97.25M | USD 10.87M | USD 675.30M |
| FY2023 | USD 60.00M | -USD 78.96M | -USD 70.85M | n/a | -1.39 | USD 186.73M | USD 1.14M | USD 336.68M |
| FY2022 | USD 26.58M | -USD 127.39M | -USD 108.93M | n/a | -2.6 | USD 125.74M | USD 4.80M | USD 215.61M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 9.74B | 145.2 | n/a | n/a |
| 2025 | 2025-12-31 | USD 5.47B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.36B | 9.2 | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.32B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 536.75M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.64B | n/a | n/a | n/a |
About Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Protagonist Therapeutics Inc's market cap?
Protagonist Therapeutics Inc's market capitalization is USD 9.74B.
What is Protagonist Therapeutics Inc's P/E ratio?
Protagonist Therapeutics Inc's price-to-earnings (P/E) ratio is 145.2.
What does Protagonist Therapeutics Inc do?
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera.